Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H11NO3.ClH |
| Molecular Weight | 157.5961 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(C(CO)(CO)N)O.Cl
InChI
InChIKey=QKNYBSVHEMOAJP-UHFFFAOYSA-N
InChI=1S/C4H11NO3.ClH/c5-4(1-6,2-7)3-8;/h6-8H,1-3,5H2;1H
DescriptionCurator's Comment:: Description was created based on several sources, including
https://www.drugs.com/pro/tham.html
https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C47775
http://www.cir-safety.org/sites/default/files/Tromet_092013_Rep.pdf
Curator's Comment:: Description was created based on several sources, including
https://www.drugs.com/pro/tham.html
https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C47775
http://www.cir-safety.org/sites/default/files/Tromet_092013_Rep.pdf
Tromethamine is extensively used in biochemistry and molecular biology. Because tromethamine (in the form of R-NH2) is a proton acceptor with a pK of 7.8, it is an effective buffer that can
be used to maintain the pH of body fluids. Tromethamine is indicated for the prevention and correction of metabolic acidosis. When administered intravenously as a 0.3 M solution, tromethamine acts as a proton acceptor and prevents or corrects acidosis by actively binding hydrogen ions (H+). It binds not only cations of fixed or metabolic acids, but also hydrogen ions of carbonic acid, thus increasing bicarbonate anion (HCO3‾). TromeThamine also acts as an osmotic diuretic, increasing urine flow, urinary pH, and excretion of fixed acids, carbon dioxide and electrolytes. A significant fraction of tromethamine (30% at pH 7.40) is not ionized and therefore is capable of reaching equilibrium in total body water. This portion may penetrate cells and may neutralize acidic ions of the intracellular fluid.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006816 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Tham Approved Useindicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease:
Metabolic Acidosis Associated with Cardiac Bypass Surgery.
Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures.
Correction of Acidity of ACD Blood in Cardiac Bypass Surgery.
It is well known that ACD blood is acidic and becomes more acidic on storage. TromeThamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromeThamine may be indicated during cardiac bypass surgery should metabolic acidosis appear.
Metabolic Acidosis Associated with Cardiac Arrest. Launch Date-1.27699198E11 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). | 2000 Apr |
|
| Characterization of the mouse Dazap1 gene encoding an RNA-binding protein that interacts with infertility factors DAZ and DAZL. | 2001 |
|
| Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. | 2001 |
|
| Cell adhesion and signaling on the fibronectin 1st type III repeat; requisite roles for cell surface proteoglycans and integrins. | 2001 |
|
| Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons. | 2001 |
|
| Early events in the polymerization of fibrin. | 2001 |
|
| Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. | 2001 |
|
| Dimerization of receptor protein-tyrosine phosphatase alpha in living cells. | 2001 |
|
| Requirements for activation and RAFT localization of the T-lymphocyte kinase Rlk/Txk. | 2001 |
|
| Possible effects of counterions on biological activities of anionic surfactants. | 2001 Apr |
|
| The structure of human mitochondrial branched-chain aminotransferase. | 2001 Apr |
|
| Capillary electrochromatographic evaluation of vitamin E-active oil constituents: tocopherols and tocotrienols. | 2001 Apr 13 |
|
| A structure-function study of ligand recognition by CD22beta. | 2001 Apr 20 |
|
| Evidence for specific ceramidase present in the intestinal contents of rats and humans. | 2001 Aug |
|
| Lipopolysaccharide stimulates norepinephrine efflux from the rat hypothalamus in vitro: blockade by soluble IL-1 receptor. | 2001 Aug 3 |
|
| Mg2+-linked oligomerization modulates the catalytic activity of the Lon (La) protease from Mycobacterium smegmatis. | 2001 Aug 7 |
|
| Spatial open-network formed by mixed triblock copolymers as a new medium for double-stranded DNA separation by capillary electrophoresis. | 2001 Feb |
|
| Renal effects of serine-7 analog of lymphoguanylin in ex vivo rat kidney. | 2001 Feb |
|
| Targeting neighbouring poly(purine.pyrimidine) sequences located in the human bcr promoter by triplex-forming oligonucleotides. | 2001 Feb |
|
| Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. | 2001 Feb |
|
| Comparison of spontaneous and noradrenaline-evoked non-selective cation channels in rabbit portal vein myocytes. | 2001 Feb 1 |
|
| Structure of soybean seed coat peroxidase: a plant peroxidase with unusual stability and haem-apoprotein interactions. | 2001 Jan |
|
| Alpha-galactosidases from the larval midgut of Tenebrio molitor (Coleoptera) and Spodoptera frugiperda (Lepidoptera). | 2001 Jan |
|
| Bcl-2 inhibits apoptosis of spermatogonia and growth of spermatogonial stem cells in a cell-intrinsic manner. | 2001 Jan |
|
| Recombinant chemosensory protein (CSP2) from the moth Mamestra brassicae: crystallization and preliminary crystallographic study. | 2001 Jan |
|
| Aqueous solution speciation of Fe(III) complexes with dihydroxamate siderophores alcaligin and rhodotorulic acid and synthetic analogues using electrospray ionization mass spectrometry. | 2001 Jan 1 |
|
| Determination of phenols in soil by supercritical fluid extraction-capillary electrochromatography. | 2001 Jan 12 |
|
| Long-term preservation of chilled canine semen: effect of commercial and laboratory prepared extenders. | 2001 Jan 15 |
|
| Analysis of glutathione by capillary electrophoresis based on sample stacking. | 2001 Jul |
|
| Application of capillary electrophoresis for organic acid analysis in herbal studies. | 2001 Jul |
|
| Separation of stilbenes by capillary electrophoresis and high-performance liquid chromatography. | 2001 Jul |
|
| Basic fibroblast growth factor inhibits choriocapillaris atrophy in rabbit. | 2001 Jul |
|
| A novel interaction between type IV pili of Neisseria gonorrhoeae and the human complement regulator C4B-binding protein. | 2001 Jun 1 |
|
| Short-chain fatty acids enhance diffusional ca transport in the epithelium of the rat cecum and colon. | 2001 Jun 22 |
|
| Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. | 2001 Mar |
|
| Determination of 8-chloroadenosine 3',5'-monophosphate in dog plasma by capillary electrophoresis. | 2001 Mar |
|
| Therapy of malignant intracranial hypertension by controlled lumbar cerebrospinal fluid drainage. | 2001 May |
|
| Stereospecificity of myo-inositol hexakisphosphate dephosphorylation by a phytate-degrading enzyme of baker's yeast. | 2001 May |
|
| Considerations necessary in gathering occurrence data for selected unstable compounds in the USEPA Unregulated Contaminant Candidate List in USEPA Method 526. | 2001 May 1 |
|
| Semipreparative capillary electrochromatography. | 2001 May 1 |
|
| Conformation of a purified "spontaneously" inserting thylakoid membrane protein precursor in aqueous solvent and detergent micelles. | 2001 May 4 |
|
| Maltodextrin-anionic surfactant interactions: isothermal titration calorimetry and surface tension study. | 2001 Oct |
|
| Characterization of a 5'-aldehyde terminus resulting from the oxidative attack at C5' of a 2-deoxyribose on DNA. | 2001 Oct |
|
| A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage. | 2001 Oct |
|
| Generation of live rat offspring by intrauterine insemination with epididymal spermatozoa cryopreserved at -196 degrees C. | 2001 Sep |
|
| Preservation of metabolic reserves and function after storage of myocytes in hypothermic UW solution. | 2001 Sep |
|
| Phosphate ion channels in sarcoplasmic reticulum of rabbit skeletal muscle. | 2001 Sep 15 |
Patents
Sample Use Guides
Usual Adult Dose for Metabolic Acidosis
Associated with Cardiac Bypass Surgery:
Initial dose: 500 mL (150 mEq) by slow intravenous infusion is considered adequate for most adults; up to 1000 mL may be required in severe cases
Maximum dose: 500 mg/kg (227 mg/lb) over a period of not less than one hour
Associated with Cardiac Arrest:
If the chest is open: 2 to 6 g (62 to 185 mL of a 0.3 M solution) injected into the ventricular cavity
If the chest is not open: 3.6 to 10.8 g (111 to 333 mL of a 0.3 M solution) injected into a larger peripheral vein if the chest is not open
Comment: Do not inject into the cardiac muscle
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1185-53-1
Created by
admin on Sat Jun 26 04:56:55 UTC 2021 , Edited by admin on Sat Jun 26 04:56:55 UTC 2021
|
PRIMARY | |||
|
1311534
Created by
admin on Sat Jun 26 04:56:55 UTC 2021 , Edited by admin on Sat Jun 26 04:56:55 UTC 2021
|
PRIMARY | RxNorm | ||
|
383V75M34E
Created by
admin on Sat Jun 26 04:56:55 UTC 2021 , Edited by admin on Sat Jun 26 04:56:55 UTC 2021
|
PRIMARY | |||
|
214-684-5
Created by
admin on Sat Jun 26 04:56:55 UTC 2021 , Edited by admin on Sat Jun 26 04:56:55 UTC 2021
|
PRIMARY | |||
|
SUB39625
Created by
admin on Sat Jun 26 04:56:55 UTC 2021 , Edited by admin on Sat Jun 26 04:56:55 UTC 2021
|
PRIMARY | |||
|
93573
Created by
admin on Sat Jun 26 04:56:55 UTC 2021 , Edited by admin on Sat Jun 26 04:56:55 UTC 2021
|
PRIMARY | |||
|
1185-53-1
Created by
admin on Sat Jun 26 04:56:55 UTC 2021 , Edited by admin on Sat Jun 26 04:56:55 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
